摘要
目的:了解5-羟色胺1A(5-HT1A)受体激动剂治疗遗传性小脑共济失调的有效性。方法:根据入选标准收集文献;依据Meta分析方法,应用RevMan 4.3.2软件计算5-HT1A受体激动剂治疗组和安慰剂对照组改善小脑功能评分的标准化均数差(SMD)及95%的可信区间(CI)。结果:5-HT1A受体激动剂治疗组与安慰剂对照组改善小脑功能评分的SMD及95%CI分别为-0.36,(-2.29,1.59);2组疗效无显著性差异(Z=0.36,P=0.359)。结论:目前的临床资料尚不能证实5-HT1A受体激动剂能有效改善遗传性小脑共济失调症状。
Objective： To explore the effect of 5-hydroxytryptamine 1A（5-HT1A） receptor agonists on hereditary cerebellar ataxia.Methods： The reports were obtained based on selection criteria.According to Meta-analysis method,the RevMan 4.3.2 software was applied to estimate the Standard Means Deviation（SMD）and 95% Confidence Interval（CI） of improving the cerebellum functional score between 5-HT1A receptor agonists treatment group and placebo control group.Results： The SMD and 95% CI of improving the cerebellum functional score between the two groups were-0.36,and（-2.29,1.59）respectively.There was no significant difference in the outcome between the two groups（Z=0.36,P=0.359）.Conclusion： The current clinical data could not confirm that 5-HT1A receptor agonists could effectively ameliorate the symptoms of hereditary cerebellar ataxia.Key kords：5-HT1A receptor agonists;hereditary cerebellar ataxia;Meta-analysis
出处
《神经损伤与功能重建》
2012年第1期40-43,共4页
Neural Injury and Functional Reconstruction
